Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial
Abstract
Soft-tissue sarcomas (STS) in the extremities and trunk treated with standard-of-care preoperative external beam radiation therapy (EBRT) followed by surgical resection are associated with local and distant relapses. In preclinical studies, oncolytic virotherapy in sarcoma has demonstrated antitumor effects via direct intratumoral oncolysis and cytotoxic T-cell–mediated immune responses. Talimogene laherparepvec (TVEC) is a replication-competent, immune-enhanced, oncolytic herpes simplex virus type 1 engineered for intratumoral injection; it has been approved by the FDA for the treatment of locally advanced and metastatic melanoma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2021
- Source ID
- 10.1136/jitc-2021-003119
Entities
People
- Benjamin J Miller
- Bryan Allen
- Carryn Anderson
- Catherine Metz
- Chinemerem Abanonu
- David Kuehn
- Jon Houtman
- Jon Thomason
- K.d. Zamba
- Laura Stephens
- Lei Wang
- Maheen Rajput
- Mohammed Milhem
- Munir Tanas
- Omar Jaber
- Sarag Boukhar
- Sarah Mott
- Stacey Hartwig
- Steven Varga
- Sudershan Bhatia
- Varun Monga
- Weizhou Zhang
Organizations
- Amgen
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense